Core Insights - The article discusses three dividend-paying stocks that are currently facing challenges regarding their dividend sustainability, highlighting the importance of dividend growth for long-term investment returns [1][19]. Company Summaries AbbVie - AbbVie is a pharmaceutical company with a market capitalization of $300 billion, known for drugs like Skyrizi and Botox [3]. - The stock has declined by 16% year-to-date and offers a quarterly dividend of $1.64 per share, resulting in an annual yield of 3.5% [3]. - AbbVie has a concerning payout ratio of 266%, indicating potential risks to its dividend payments [4]. - Sales of Humira, a key drug, have dropped by 51% to $1.1 billion in fiscal Q1 2025 compared to the previous year, contributing to a 69% decline in net income over the trailing 12 months [5]. - The company's net debt has increased by 24% over the past two years to $64.7 billion, raising doubts about the future of its dividend [6]. - However, AbbVie's next-generation drugs, Skyrizi and Rinvoq, generated $5.1 billion in fiscal Q1 2025, a 65% increase year-over-year, with expectations of continued growth [7]. Medtronic - Medtronic is a medical device company with a focus on cardiac devices and surgical tools, currently down 37% from its 2021 highs [8]. - The company has paid and raised its dividend for 47 consecutive years, with a current quarterly dividend of $0.70 per share, yielding 3.3% annually [9]. - Medtronic's payout ratio stands at 84.7%, with a reported net income of $1.29 billion in fiscal Q3 2024, reflecting a 2% decline year-over-year [10]. - Despite revenue reaching all-time highs, net income has not significantly grown in a decade, partly due to the company's extensive acquisition strategy [11]. - Medtronic holds $18.6 billion in net debt, with servicing costs of $757 million over the past year, although it has reduced debt by 8% from recent highs [12][13]. Pfizer - Pfizer is a well-known pharmaceutical company with a history of 176 years, recently recognized for its COVID-19 vaccine [15]. - The company offers a quarterly dividend of $0.43 per share, yielding 7.6%, but its stock has fallen 63% from pandemic highs [16]. - Pfizer's payout ratio is 121.5%, raising concerns about its ability to maintain dividend increases for the 17th consecutive year [16]. - The company reported an 8% decline in revenue for Q1 2025, with total revenue of $13.7 billion, down from $14.9 billion in Q1 2024, largely due to a 76% drop in sales of its COVID-19 product, Paxlovid [17]. - Pfizer has averaged over $10 billion in R&D spending annually, while also managing $44 billion in net debt, which it has reduced by 31% in less than a year [18].
Don't Fall for These 3 Dividend Stocks: They May Have to Make a Cut.